Following Roche’s community letter announcing the discontinuation of GENERATION HD2, and EHDN’s Executive Committee statement, we will welcome Peter McColgan, Global Development Leader at Roche, to present the results and key learnings from the Phase 2 clinical trial testing tominersen in Huntington’s disease.

📅Date: Tuesday, 29 September 2026 🕓Time: 16:00–17:30 CEST  📍Format: Virtual (Zoom) Register Now!

EHDN Chair Patrick Weydt and Deputy Chair Åsa Petersén will host the meeting, which will also feature an expert panel discussion and Q&A session.